Biopharmaceutical Process Analytical Technology Market is Expected to Reach $2.6 billion | MarketsandMarkets™
May 31, 2024 08:30 ET
|
MarketsandMarkets Research Pvt. Ltd.
Chicago, May 31, 2024 (GLOBE NEWSWIRE) -- Biopharmaceutical Process Analytical Technology market in terms of revenue was estimated to be worth $1.2 billion in 2024 and is poised to reach $2.6...
HealthPRO Canada Delivers Tangible Sustainability Strategies to Empower Healthcare Organizations
May 31, 2024 08:30 ET
|
HealthPRO Canada
Oakville, ON, May 31, 2024 (GLOBE NEWSWIRE) -- HealthPRO Canada’s third annual Sustainability Rounds event recently brought together more than 200 stakeholders from across the supply chain to...
Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus
May 31, 2024 08:00 ET
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus
Iterum Therapeutics Receives FDA Acceptance of Resubmission of NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections
May 31, 2024 08:00 ET
|
Iterum Therapeutics PLC
DUBLIN and CHICAGO, May 31, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV...
TG Therapeutics Announces Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting
May 31, 2024 07:30 ET
|
TG Therapeutics, Inc.
NEW YORK, May 31, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting study designs for post-marketing studies being undertaken for...
atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference
May 31, 2024 07:00 ET
|
atai Life Sciences
NEW YORK and BERLIN, May 31, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental...
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
May 31, 2024 01:05 ET
|
Regeneron Pharmaceuticals, Inc.
Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent significantly reduced exacerbations and improved...
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
May 31, 2024 01:00 ET
|
Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y. and PARIS, May 31, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the U.S. Food and Drug Administration (FDA) has extended by...
ADC Therapeutics nimmt an der Jefferies Global Healthcare Conference teil
May 30, 2024 19:40 ET
|
ADC Therapeutics SA
LAUSANNE, Schweiz, May 31, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) gab heute bekannt, dass Ameet Mallik, Chief Executive Officer, am Donnerstag, 6. Juni 2024 um 11:30 Uhr ET an der...
Syncromune, Inc. Announces FDA Clearance of IND Application for SYNC-T SV-102, a First-In-Class Combination Multi-Target Immunotherapy for Metastatic Castrate-Resistant Prostate Cancer
May 30, 2024 19:22 ET
|
Syncromune
SYNC-T SV-102 Therapy combines partial tumor oncolysis with a fixed-dose combination multi-target biologic drug to provide a novel, personalized therapeutic approach for the treatment of metastatic...